Bispecific antibody meets survival goal in lung cancer study, Akeso reports
Akeso announced positive updated Phase 3 results for its PD-1xVEGF bispecific antibody ivonescimab in a subset of lung cancer patients, meeting the overall survival endpoint. The outcome follows an earlier interim analysis that had raised doubts among investors. The company now claims a definitive win in this patient population.
The updated Phase 3 data marks a notable shift in momentum for Akeso's investigational therapy, which targets both PD-1 and VEGF pathways in a single molecule. Earlier interim results had left investors uncertain about the drug's efficacy, but the latest analysis shows a clear overall survival benefit in a defined lung cancer subgroup. This dual-mechanism approach is part of a broader trend in oncology toward bispecific antibodies, which aim to improve upon single-target immunotherapies by addressing multiple drivers of tumor growth simultaneously. The confirmation of a survival advantage strengthens the drug's clinical rationale and could position it as a competitive option in a crowded lung cancer treatment landscape, though regulatory review and broader patient data remain ahead.
This result may affect lung cancer patients seeking new treatment options, particularly those in the subgroup where survival improved. If confirmed in broader analyses, the therapy could offer an alternative to existing checkpoint inhibitors, potentially extending life for some individuals. Investors and biotech firms may also feel the ripple effects, as positive data can influence funding decisions and research priorities. However, the true societal impact depends on regulatory approvals, real-world effectiveness, and accessibility, which remain uncertain at this stage.